Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension

BACKGROUND AND OBJECTIVES: Macitentan (MAC) reduces morbidity and mortality among advanced-stage pulmonary arterial hypertension (PAH) patients. However, data regarding the histopathologic and hemodynamic benefits of MAC treatment at an early stage of PAH is lacking. METHODS: One week after monocrot...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kyung-Hee, Kim, Hyung-Kwan, Chan, Stephen Y., Kim, Yong-Jin, Sohn, Dae-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110709/
https://www.ncbi.nlm.nih.gov/pubmed/30088353
http://dx.doi.org/10.4070/kcj.2017.0394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110709/
https://www.ncbi.nlm.nih.gov/pubmed/30088353
http://dx.doi.org/10.4070/kcj.2017.0394

Ejemplares similares